The U.S. Food and Drug Administration (FDA) has approved a new drug called Decnupaz (decnupaz) for adults with a rare and aggressive blood cancer known as blastic plasmacytoid dendritic cell neoplasm (BPDCN). Decnupaz is a targeted therapy that works by attaching to a protein called CD123 on cancer cells and delivering a chemotherapy agent directly to them. This approval provides a new treatment option for patients with BPDCN, a disease that historically has had very limited therapies.
Decnupaz is given as an intravenous infusion once every three weeks. The recommended dose is based on body weight. Before each infusion, patients must receive medications to reduce the risk of infusion reactions, such as corticosteroids, antihistamines, and fever reducers. Treatment continues as long as it is working and the side effects are manageable.
This approval is based on clinical studies showing that Decnupaz can shrink tumors in some patients with BPDCN. However, it is not a cure. Patients should talk to their doctor about whether Decnupaz is right for them, especially given the risk of serious side effects like liver problems, fluid retention, and infusion reactions. As with any new drug, ongoing monitoring is important.